Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the <i>IDH1</i> or <i>IDH2</i> Mutation Status.

Venneker, Sanne; Kruisselbrink, Alwine B; Briaire-de Bruijn, Inge H; de Jong, Yvonne; van Wijnen, Andre J; Danen, Erik H J; Bovée, Judith V M G

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.

Venneker, Sanne; Kruisselbrink, Alwine B; Briaire-de Bruijn, Inge H; de Jong, Yvonne; van Wijnen, Andre J; Danen, Erik H J; Bovée, Judith V M G.

Afiliación

Venneker S; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Kruisselbrink AB; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Briaire-de Bruijn IH; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
de Jong Y; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
van Wijnen AJ; Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Danen EHJ; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC Leiden, The Netherlands.
Bovée JVMG; Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

Cancers (Basel) ; 11(12)2019 Dec 02.

Article en En | MEDLINE | ID: mdl-31810230

Palabras clave

AGI-5198; D-2-hydroxyglutarate; chondrosarcoma; isocitrate dehydrogenase; radiotherapy; sarcoma; talazoparib; temozolomide

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2019 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google